Aim: The aim was to identify benefit thresholds for clinical variables. We hypothesize, if variables fall below or exceed these threshold levels, systemic amoxicillin/ metronidazole may contribute to reducing progression of periodontitis.
| INTRODUC TI ON
In industrialized countries, approximately 50% of the adult population suffer from moderate or severe periodontitis (Eke, Dye, Wei, Thornton-Evans, & Genco, 2012; Holtfreter, Kocher, Hoffmann, Desvarieux,&Micheelis,2010) .Periodontitisiscausedbymicrobial biofilms (Darveau, 2010; Paster etal., 2001; Socransky, Haffajee, Cugini,Smith,&Kent,1998) andisclinicallycharacterizedbyperiodontal pocket formation and attachment loss. Teeth affected by periodontitis may lose function and need to be extracted, which often requires costly prosthetic rehabilitations. Periodontal therapy usually is aimed to disrupt tooth adhering biofilm and reduce probing depths,followedbylifelongmaintenancetherapy (AAP,2000) .
There is a large body of evidence that mechanical debridement in moderate to severe periodontitis patients could be successfully supplemented by systemic antimicrobials, such as amoxicillin and metronidazole (Keestra, Grosjean, Coucke, Quirynen, & Teughels, 2015; Sgolastra,Gatto,Petrucci,&Monaco,2012) .Therationalefor the adjunctive antimicrobials is to exert an additional antimicrobial effect during mechanical therapy and further improve the clinical parameters, especially at severely affected sites (Borges et al., 2017; Ehmke, Beikler, Milian, & Flemmig, 2005) . Retrospective cohort studieshavedetectedahigherriskoftoothlossasproportionsof persistent probing depths increase (Matuliene et al., 2008; McGuire &Nunn,1996) .Itiswellestablishedthatadjunctiveamoxicillinand metronidazole are even more effective in reducing deep pockets compared to mechanical debridement alone (Feres etal., 2012; Mombellietal.,2013) .TomasiandWennströmhaverecentlyfound that assessing further attachment loss after treatment is far more appropriatethanassessingattachmentgains (Tomasi&Wennström, 2017) .TheABPAROstudyappliedthesurrogateparameter,further attachment loss, to evaluate the benefit of systemic antimicrobials adjunctive for subgingival debridement. However, it remains unclear whether disease progression is reduced, for example if further attachment loss and furcation involvement changes are limited (Eickholzetal.,2016; Harksetal.,2015) .Therefore,regardingadaily routine, it would be very helpful to have clinical thresholds to determine to what extent adjunctive antimicrobials are effective to prevent further disease progression.
The current explorative analysis of a large multi-centre trial aims to identify thresholds for distinct clinical variables for which the application of adjunctive antimicrobials is associated with better clinical outcomes. We hypothesized that younger patients and those whose disease was more severe would receive greater benefits from empiric adjunctive antimicrobials.
| PATIENTS AND ME THODS

| Study design
This is an exploratory analysis of the per-protocol collective from the prospective, randomized, stratified, double-blind, multi-centre ABPARO trial (Clinical Trials.gov NCT00707369) over a period of 27.5months (Eickholzetal.,2016; Harksetal.,2015) .Thetrialexaminedtheeffectofsystemicamoxicillin(500mg)andmetronidazole (400mg; 3×/day for 7days) adjunctive on mechanical subgingival debridement using clinical parameters in patients suffering from moderate to severe periodontitis. Antimicrobials were prescribed empirically, that is without prior analysis of intra-oral bacteria. As formerly described (Harks etal., 2014 (Harks etal., , 2015 , patients who followedtheprotocolandtookthetwoprescribeddrugsasscheduled
Conclusions:
The clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age.
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Clinical Relevance
Scientific rationale for study: Systemic amoxicillin and metronidazole are established adjuncts for periodontitis therapy; however, it is unclear which patients will benefit from this.
Identifying benefit thresholds from clinical parameters may also help to identify patients in whom, if their values fall short of or exceed these thresholds, the progression of periodontitis may be reduced. Quad-block patient randomization lists were computergenerated for each stratum per centre (1:1 allocation ratio). This statistician was not involved in further trial affairs. Randomization lists for participating centres were stored exclusively at the study centre.
| Examinations and endpoints
All measurements were conducted by blinded and calibrated examinersnotinvolvedintherapy (Harksetal.,2014 (Harksetal., ,2015 .Full-mouth periodontal measurements were performed at six sites for each tooth:primarilyrelativeattachmentlevel(RAL)measurements,corresponding to the distance from occlusal surface to the bottom of the periodontal pocket (Florida Disk probe, Gainesville, FL, USA).
The differences between baseline and 27.5-month RAL readings reveal the changes to the clinical attachment level (gain or loss of tooth-supportingtissue).Theprimaryendpointwastheproportion ofsitesperpatientwithnewclinicalattachmentloss(PSAL)≥1.3mm between the initial visit and the post-27.5-month visit. Among others, the following secondary endpoints were assessed exploratorily: PPD,attachmentlevel(sumofgingivalrecessionandPPD)andgingivalbleedingonprobing(BOP, Lang,Adler,Joss,&Nyman,1990) .
These parameters were used to define a clinical threshold value for the prescription of adjunctive systemic antimicrobials (see statistical analysis).
| Periodontal therapy
Each patient received 12 examinations and/or therapy visits over the 27.5-month study period. After the baseline examination, patients received supra-and subgingival debridement in up to two sessions on two consecutive days. All mechanical therapy was performed with hand instruments and/or machine-driven scalers. 
| Statistical analysis
Standard univariate statistical analyses were applied. Categorical The combination of thresholds for age and % PPD≥5mm (% PPD≥5mm<35 and age<55% PPD≥5mm<35 and age≥55%
PPD≥5mm≥35 and age<55% PPD≥5mm≥35 and age≥55)
was examined in an univariate analysis to determine if the treatment effect on clinical attachment loss differed among the categories. A multivariable analysis was performed to adjust for possible imbalances between the subgroups. Confounders were first identified using univariate methods (Supporting Information Tables S1, S2 ).
Subsequently, a multivariable linear regression model was fitted, including the cut-off variables and potential confounders. A full de-
scriptionofthemodelisgiveninSupportingInformationTableS3.
The results are reported using least-square mean estimates, with corresponding 95% confidence limits and p-values obtained from
Wald tests.
Statistical analyses were performed using SAS software, version 9.4oftheSASSystemforWindows(SASInstitute,Cary,NC,USA).
Inferentialstatistics,likep-values and confidence intervals, were intended to be exploratory, not confirmatory. Therefore, neither global nor local significance levels were determined, and no adjustment for multiplicity was applied. Consequently, explorative p-values≤0.05
were denominated as statistically noticeable instead of significant.
| RE SULTS
| Patients
Of the 506 randomized patients, 345 patients who followed the study protocol during the 27.5-month period and took all tablets within 6-8 days, according to their medication diaries, were included in the per-protocol collective (345 patients, placebo: n = 175, antimicrobials: n =170).Forbaseline,demographicandclinicalcharacteristics see Tables 1 and 2 , respectively. Based on the clinical and demographic characteristics, the patients were rather a sample of chronic periodontitis.
Before the thresholds were determined, Spearman correlations 
| Clinical threshold values
| Age at baseline
Patients were classified based on their age at baseline into the followingtwosubgroups:age<55years(placebo:n =103,antimicrobials: n =94)and≥55years(placebo:n = 71, antimicrobials: n =76). 
| Mean attachment level at baseline
Regarding initial mean clinical attachment level, a threshold value
was identified when the mean value was<5mm or≥5mm. If the meanclinicalattachmentlevelwas≥5mm,thePSAL≥1.3mmafter
27.5 months in the antimicrobial group (n =26) was 5.2% (Q25/ Q75: 3.3%/12.7%) and moreover was noticeably higher in the placebo group (n =31),with12.5%(Q25/Q75:6.3%/17.2%)(p = 0.005,
Figure2c
).Atameaninitialattachmentlevelof<5mm,thepatients in the antimicrobial group (n =144) exhibited a loss of attachment at5.3%ofsites(Q25/Q75:3.2%/9.6%),whichiscomparabletothe amount of attachment loss in the placebo group (n =144) of 6.7%
(Q25/Q75:4.4%/12.6%),respectively(p =0.005).
| Combination of PPD ≥ 5 mm and age at baseline
If both of the above-identified thresholds for baseline probing depth and age are combined, it becomes even more evident that younger patients exhibit larger numbers of deep pockets, the more the in- are<55years of age and exhibit≥35% PPD≥5mm, those in the placebo group exhibited three times more site-attachment loss compared to patients in the antimicrobial group (12% vs. 4%, respectively; p =0.003). In contrast, if patients are≥55years of age and exhibit<35% PPD≥5mm, those in both the placebo and antimicrobial groups exhibited comparable results concerning new attachment loss (6.2% vs. 6.0%, respectively; p =0.730).Formoredetails seeTable3.
| Multivariable analysis
The conducted multivariable analysis confirms the above findings (SupportingInformationTableS3).
| D ISCUSS I ON
The present sub-analysis identified benefit thresholds for the following parameters: age, initial percentage and numbers of sites with
PPD≥5mmandmeaninitialattachmentlevel>5mm.Attheselevels, the application of adjunctive systemic amoxicillin and metronidazole is associated with better clinical outcomes. However, it was not possible to define a threshold value for initial BOP.
For the present analysis, clinical and demographic parameters had already been routinely obtained before or during the periodontal examinations and could be calculated from those (e.g. clinical attachmentlevel).Therefore,thesuggestedthreshold-relatedstrategy to determine whether or not to prescribe adjunctive antimicrobials can easily be adapted to one's daily routine without additional effort. However, the threshold values should be seen as a helpful orientation, and by no means as a strict rule regarding the application of antimicrobials, because the mean variation of our data indicates that individual patients above or below or above the threshold may benefit or not. This is also documented in the probabilities presented inTable3.
The main effect of adjunctive systemic antimicrobials is the improved reduction of deep pocket sites compared to mechanical therapy alone (Mombelli, Almaghlouth, Cionca, Courvoisier, & Giannopoulou, 2015; Silva etal., 2011) . Small proportions of deep pockets after therapy may reduce the need for surgery and ease maintenance therapy, because higher numbers of teeth with residual deeppocketswouldplausiblyrequireamorelaboriousmaintenance therapy. In the present study, the results regarding the percentage of sites with new attachment loss were statistically noticeable different (p <0.05) between the antimicrobial and placebo groups, in both patients exceeding the 35% threshold for PPD≥5mm and in patients with PPD≥5mm below the 35% threshold (Figure2a).
However, the absolute difference between antimicrobials and placebo patients at and above the 35% threshold was approximately 7% points, and a difference of this magnitude could be rated as clinically relevant (Harks etal., 2015) . In contrast, the absolute differencebetweentheantimicrobialandplacebopatientsbelowthe35%
threshold was approximately 1%, and such a small difference cannot be considered clinically relevant, despite its statistical noticeability (Figure2a) .Becauseofthehighcorrelationbetweenthenumberof proportion of PPD≥5mm. Therefore, in our study, the results for both parameters can be transferred approximately to each other.
Consideringthepatients'age,arisk-relatedtherapeuticapproach might be more appropriate, as this could lead to a more individual treatment strategy (Wennström, Papapanou, & Gröndahl, 1990 (Tonetti,Greenwell,&Kornman,2018 (Joss, Adler, & Lang, 1994; Lang, Schätzle, & Löe, 2009; Lang etal.,1990) .AbsenceofBOPduringmaintenanceisassociatedwith periodontal stability (Joss etal., 1994) . However, the level of this parameter at baseline failed to indicate the predictive value of either the antimicrobial group or the placebo group, in regard to the proportion of new attachment loss after 27.5 months. Due to even distribution of initial bleeding and later attachment loss events, no Againstthebackgroundanddangerofincreasingmicrobiological resistance, systemic antibiotics for treating non-life threatening diseases should be prescribed with caution. Increased appearance of bacterial resistance is strongly related to the frequency of antibiotic drug consumption. Therefore, the described thresholds for clinical parameters may help to identify groups of patients which profit more than others, that is with less new attachment loss, from adjunctive systemic antimicrobial therapy.
In conclusion, the clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age.
Clinicians treating patients similar to the population presented in this sub-analysis may consider the reported beneficial thresholds as an additional decision-making aid in regard to the use of systemic amoxicillin/metronidazole. In terms of generalizability, it would be interesting to investigate whether these newly identified beneficial thresholds are also suitable for other populations.
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